Effect of Qinghuang Powder () Combined with Bupi Yishen Decoction () in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation.
10.1007/s11655-018-2554-9
- Author:
Qing-Bing ZHOU
1
;
Xiao-Hong YANG
1
;
Hong-Zhi WANG
1
;
De-Xiu WANG
1
;
Yong-Gang XU
1
;
Xiao-Mei HU
1
;
Feng-Qin XU
1
;
Rou MA
2
Author Information
1. National Hematological Medical Center of Traditional Chinese Medicine, Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
2. National Hematological Medical Center of Traditional Chinese Medicine, Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. xyxysys@163.com.
- Publication Type:Clinical Trial
- Keywords:
Bupi Yishen Decoction;
Chinese medicine;
Qinghuang Powder;
demethylation;
myelodysplastic syndromes
- MeSH:
Arsenicals;
administration & dosage;
pharmacology;
therapeutic use;
Cell Lineage;
drug effects;
DNA Methylation;
drug effects;
Demethylation;
Drugs, Chinese Herbal;
administration & dosage;
pharmacology;
therapeutic use;
Female;
Gene Ontology;
Humans;
Leukocyte Disorders;
drug therapy;
genetics;
Male;
Middle Aged;
Powders;
Treatment Outcome
- From:
Chinese journal of integrative medicine
2019;25(5):354-359
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To explore the effect of Qinghuang Powder (QHP,()combined with Bupi Yishen Decoction (BPYS, ) on myelodysplastic syndromes (MDS) patients with refractory cytopenia with multilineage dysplasia (RCMD) and determine the change of DNA methylation in MDS-RCMD patients after the treatment of Chinese medicine formula.
METHODS:All 308 MDS-RCMD patients were treated with QHP combined with BPYS for 2 months at least, absolute neutrophil count (ANC), hemoglobin (Hb), platelets (PLT), primitive bone marrow cells and chromosome karyotype were chosen as the main evaluation indexes to analyze the treatment effect according to criteria from the MDS International Working Group. Then 43 bone marrow samples from 15 MDS-RCMD patients and 28 healthy donors were obtained for the examination of DNA methylation. Gene Ontology (GO) and Pathway analysis were applied to analyze the methylation data.
RESULTS:The overall MDS response rate to QHP was 61.68% (190/360) including hematologic improvement-neutrophil (HI-N) or hematologic improvement-erythroid (HI-E) or hematologic improvement-platelet (HI-P). Patients with anemia had a better response rate than patients with neutropenia or thrombocypenia (55.88% vs 31.54% or 55.88% vs. 36.9%). The DNA methylation microarray analysis disclosed that 4,257 hypermethylated genes were demethylated upon the treatment with QHP and BPYS. GO analysis and Pathway analysis showed that these demethylated genes were involved in a lot of tumor-related pathways and functions.
CONCLUSIONS:QHP combined with BPYS could effectively treat MDS-RCMD patients through hematologic improvement (HI-N, HI-P or HI-E) and PLT and RBC transfusion independence due to the demethylation, thereby providing another choice for the treatment of patients with MDS-RCMD.
